In vitro and in vivo anti-tumor extrapolation of one pot engineered stimuli-responsive poly(ethylenimine) and (phenylthio) acetic acid ion pair micelles for smart delivery of doxorubicin and indocyanine green
Garima Sharma,Soo Chan Park,Kwanjira Wangpimool,Yu-yuan Guo,Hyeon Ki Son,Song-rae Kim,Jin-Chul Kim
DOI: https://doi.org/10.1016/j.jddst.2023.104845
IF: 5
2023-08-26
Journal of Drug Delivery Science and Technology
Abstract:Here, an ionic pair self-assembled micellar nanoparticles (∼130 nm diameter) are constructed using poly(ethylenimine) (PEI) and (phenylthio) acetic acid (PTA) for dual temperature- and oxidation (i.e., ROS)-responsive release of drugs. Further, Doxorubicin (DOX) and indocyanine green (ICG) were loaded in the micelles for synergistic chemo-phototherapy. The 1 H NMR and FT-IR spectrum of near-infrared (NIR)-treated micelles showed the oxidation of the sulfide group of PTA into the sulfone group, leading to the disassembly of the micelles and the release of payloads. The ICG loaded in PEI/PTA micelles enhanced ROS generation and increased temperature than free ICG. The In vitro and in vivo studies showed that NIR-treated DOX/ICG-loaded micelles showed a more effective reduction in tumor volume than free DOX, free DOX/ICG-loaded micelles, and DOX-loaded micelles at a similar dose. This is due to the NIR-mediated increase in ROS and temperature that results in the disassembly of micelles and the release of drugs. The TEM images of the excised tumors indicated cellular apoptosis. The in vivo imaging system showed increased uptake of ICG in the tumors of ICG micelles-treated mice compared to the free ICG group. Thus, these ion-pair nanocarriers showed synergistic chemo-phototherapy, putting forward a therapeutic strategy to combat cancer disease. Graphical abstract Download : Download high-res image (397KB) Download : Download full-size image The objective of this study was to prepare and characterize gelatinized tapioca starch-magnesium aluminum silicate (GTS−MAS) agglomerates for use in tablets. GTS−MAS nanocomposites were prepared using the spray drying method and agglomerated using various polyvinylpyrrolidone (PVP) contents as agglomerating agents. The prepared agglomerates exhibit improved particle flowability and enhanced particle strength. GTS could interact with PVP via H-bonds, but did not affect the thermal properties and crystallinity of the composites. The tablets prepared using the agglomerates with PVP exhibited lower hardness than those without PVP because of the particle strength effects. All agglomerates showed acceptable tablet hardness when the drug was incorporated. The addition of PVP retarded tablet disintegration and drug release in acidic and neutral media. For stability tests, humidity under accelerated conditions (45 °C, 75% RH) caused an increase in tablet hardness after 3 months of storage. However, the similarity of tablet drug release (f 2 values of 50–100) was found compared to the initial stage. Moreover, the GTS−MAS agglomerates displayed sufficient carrying capacity, and at least 30% of the drug powder could be added to achieve the desired tablets. These findings suggest that the agglomerates of GTS−MAS nanocomposites provide acceptable diluent features for utilization in directly compressed tablets. Cancer as a disease that endangers millions of lives annually has a dynamic nature, and one of the most critical challenges to finding an effective method to treat cancer is the emergence of a resistance mechanism. It is worth mentioning that it is suitable to change the strategy in cancer treatment from finding new ways to enhancing existing effective and innovative treatments. One of the most common methods of cancer treatment is chemotherapy, but untargeted chemotherapy attacks both tumor cells and non-cancerous ones. The use of nanotechnology could be a solution since it can improve therapies and enable them to target more precisely, increase localized drug efficacy, increase dual-drug loading, and decrease systemic toxicity to counteract resistance mechanisms. A common cancer in the urogenital region is bladder cancer which has a high rate of occurrence and relapse. The effect of Mitomycin C on bladder cancer therapy has been investigated extensively in recent years. MMC is a highly potent antibiotic isolated from Streptomyces caespitosus and can cause cell death. Although MMC can prevent and bypass multidrug resistance (MDR) development, the therapeutic effect may be restricted because it may cause prolonged damage to some tissues. Extensive research has been done on potential ways to enhance the administration of MMC. Despite the most effective methods of giving MMC, many bladder cancer still occur. The application of MMC and other agents targeting various pathways in a combination therapy method could be a way to overcome treatment resistance because this method is unlikely to have cross-resistance. Moreover, to improve the targeting ability o -Abstract Truncated-
pharmacology & pharmacy